KEVIN LEE: Open Payments
NPI 1306405030 · SALINAS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,237 in 151 payments from 19 companies in 2025. Trend: 2023 $2,060 · 2024 $3,487 · 2025 $3,237
Food & beverage: $2,960Education: $277
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 17 | $454 |
| ABBVIE INC. | 23 | $417 |
| Janssen Biotech, Inc. | 15 | $338 |
| Incyte Corporation | 14 | $304 |
| Amgen Inc. | 10 | $273 |
| Arcutis Biotherapeutics, Inc. | 13 | $256 |
| Galderma Laboratories, L.P. | 10 | $198 |
| GENZYME CORPORATION | 6 | $193 |
| UCB, Inc. | 15 | $186 |
| PFIZER INC. | 6 | $133 |
Products named: DUPIXENT, TREMFYA, OPZELURA, Otezla, Zoryve, RINVOQ, SKYRIZI, NEMLUVIO.
Industry payments across CA — which companies pay providers there.
